<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Livedoid vasculopathy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Livedoid vasculopathy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Livedoid vasculopathy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark DP Davis, MD, FAAD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth J Warrington, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Livedoid vasculopathy is a chronic, painful, thrombo-occlusive cutaneous vasculopathy that involves the distal lower extremities and feet. Characteristic clinical features include livedoid skin changes (linear or angular, erythematous nodules), atrophie blanche (smooth, ivory-white plaques), and intensely painful ulcerations. The diagnosis is confirmed through a skin biopsy that demonstrates characteristic vascular abnormalities, including intraluminal thrombosis, endothelial proliferation, and subintimal hyaline degeneration.</p><p>The pathogenesis of livedoid vasculopathy is unclear. The disorder can occur either independently or in association with acquired or inherited thrombophilia or various systemic diseases.</p><p>The clinical manifestations, diagnosis, and treatment of livedoid vasculopathy are reviewed here. Cutaneous vasculitis and other causes of leg ulcers are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis"</a> and  <a class="medical medical_review" href="/z/d/html/13680.html" rel="external">"Approach to the differential diagnosis of leg ulcers"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">NOMENCLATURE</span><span class="headingEndMark"> — </span>The literature on livedoid vasculopathy is highly problematic with regard to nomenclature [<a href="#rid1">1</a>]. A variety of other terms have been used to refer to this condition, most often "atrophie blanche" and "livedoid (or livedo) vasculitis." However, "atrophie blanche" is most appropriately used as a descriptive term for the smooth, ivory-white plaques that characteristically occur in livedoid vasculopathy but may also occur in other disorders, particularly venous insufficiency. The use of "vasculitis" should be avoided because true vasculitis, as demonstrated by destructive inflammation within the blood vessel wall, is absent. (See <a class="local">'Clinical features'</a> below and <a class="local">'Pathology'</a> below.)</p><p>Less common terms that have been used to refer to livedoid vasculopathy in the literature include segmental hyalinizing vasculopathy, livedo reticularis with summer ulcerations, livedo reticularis with winter ulcerations, and <strong>p</strong>ainful <strong>p</strong>urpuric <strong>u</strong>lcers with <strong>r</strong>eticular <strong>p</strong>atterning on the <strong>l</strong>ower <strong>e</strong>xtremities (PURPLE).</p><p class="headingAnchor" id="H2197963612"><span class="h1">EPIDEMIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Livedoid vasculopathy primarily occurs in young to middle-aged adults and is more common in females than males.</p><p>The pathogenesis is not well understood but is postulated to involve increased coagulation or impaired fibrinolysis that results in occlusion of dermal blood vessels with fibrin thrombi [<a href="#rid2">2</a>]. The thrombosing occlusive vasculopathy may be associated with occlusions of the small vessels of the nerves in the dermis, leading to an "ischemic form" of peripheral neuropathy and contributing to sensory disturbances [<a href="#rid3">3</a>]. (See <a class="local">'Clinical features'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Livedoid vasculopathy occurs on the lower leg (most common site), ankle, and/or dorsal foot [<a href="#rid4">4</a>]. The presentation is often bilateral, but unilateral involvement may also occur. The characteristic clinical findings are livedoid changes and atrophie blanche. Ulceration is an additional common finding; the ischemic/infarctive ulcerations are often pinpoint and intensely painful.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Livedoid changes</strong> – Livedoid changes are deep, barely palpable, slightly erythematous macules, papules, or nodules that have a linear or angular shape. The appearance resembles patchy livedo reticularis  (<a class="graphic graphic_picture graphicRef113793" href="/z/d/graphic/113793.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrophie blanche</strong> – Atrophie blanche appears as smooth, ivory-white, atrophic plaques surrounded by hyperpigmentation and telangiectasias  (<a class="graphic graphic_picture graphicRef82968 graphicRef82969 graphicRef113792" href="/z/d/graphic/82968.html" rel="external">picture 2A-C</a>). The plaques often have small amounts of stippled pigment. Atrophie blanche can develop in sites of prior ulceration or in the absence of preceding ulcers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ulcers</strong> – Superficial ulcers are common and typically range from 1 to 5 mm in diameter  (<a class="graphic graphic_picture graphicRef113791 graphicRef52615" href="/z/d/graphic/113791.html" rel="external">picture 3A-B</a>). Larger and deeper ulcers may also occur. Removal of eschar will reveal a punched-out, angular, or stellate ulcer. </p><p></p><p>Livedoid changes are often the initial clinical manifestation of livedoid vasculopathy. Alternatively, ankle edema or small, slightly raised papules with telangiectasias or purpura and peripheral petechiae may precede livedoid changes. Ulcers are often persistent; even with treatment, healing may take several months.</p><p>Most patients with livedoid vasculopathy experience substantial pain, burning, or itching in involved areas.</p><p class="headingAnchor" id="H2706739058"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>The characteristic pathologic changes occur in the blood vessels of the upper, middle, and/or lower dermis. The blood vessels demonstrate thickening and focal thrombosis, with endothelial proliferation and hyaline degeneration of the subintimal layer [<a href="#rid5">5</a>]. The hyaline material stains positively by the periodic acid-Schiff technique but is also visualized well on hematoxylin eosin staining  (<a class="graphic graphic_picture graphicRef55773" href="/z/d/graphic/55773.html" rel="external">picture 4</a>).</p><p>The elastic laminae of involved vessels are usually preserved, and the vascular wall is rarely destroyed. Vessel lumina are occluded by proliferating cells embedded within loose, fibrinoid material. The surrounding inflammatory reaction is relatively mild and consists primarily of lymphocytes. Extravasation of red blood cells may be present.</p><p class="headingAnchor" id="H9"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>Livedoid vasculopathy can occur with or without identifiable predisposing risk factors for thrombosis. Examples of risk factors for thrombosis that have been linked to livedoid vasculopathy include antiphospholipid antibodies, paraproteinemias, and genetic disorders that predispose to thrombosis. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Inherited thrombophilia'</a>.)</p><p>Livedoid vasculopathy can also occur in the setting of a defined illness, particularly a systemic rheumatic disease. The diseases most commonly diagnosed in the setting of livedoid vasculopathy are the primary antiphospholipid syndrome, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease, and undifferentiated connective tissue disease [<a href="#rid4">4,6,7</a>].</p><p>Re-emergence of ulcers in association with coronavirus disease 2019 (COVID-19) has been reported in a patient in whom livedoid vasculopathy was previously under control [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H12"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of livedoid vasculopathy is confirmed through the detection of consistent histologic findings in a patient with suggestive physical findings (eg, livedoid changes, atrophie blanche, ulcers) on the lower extremities. The cutaneous manifestations alone are insufficient to confirm the diagnosis, as similar findings may occur in other disorders. Thus, a skin biopsy is mandatory. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>For patients with ulcers, a careful history and physical examination can be helpful for determining whether other diagnoses should be included in the differential diagnosis. The approach to the differential diagnosis of leg ulcers is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/13680.html" rel="external">"Approach to the differential diagnosis of leg ulcers", section on 'Patient evaluation'</a>.)</p><p>The ideal biopsy type is a fusiform incisional biopsy that includes subcutaneous fat. Alternatively, a 4 to 6 mm punch biopsy can be performed [<a href="#rid2">2</a>]. The optimal site for a biopsy is the edge of a new ulcer or a new purpuric papule. The histologic findings in the dermal vasculature that strongly support a diagnosis of livedoid vasculopathy are [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intraluminal thrombosis</p><p class="bulletIndent1"><span class="glyph">●</span>Endothelial proliferation</p><p class="bulletIndent1"><span class="glyph">●</span>Subintimal hyaline degeneration</p><p></p><p>Direct immunofluorescence (DIF) is estimated to show positive immunoreactants in 43 to 100 percent of patients [<a href="#rid9">9</a>]. C3 and immunoglobulin M (IgM) deposited in the blood vessels and the dermal-epidermal junction are the most common finding [<a href="#rid9">9</a>].</p><p>After the diagnosis has been confirmed histopathologically, an underlying disorder must be excluded. (See <a class="local">'Additional evaluation'</a> below.)</p><p class="headingAnchor" id="H498849275"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of livedoid vasculopathy includes a broad array of conditions that may cause skin discoloration, cutaneous ulcers, or nodules of the lower extremities. The most common disorders in the differential diagnosis are lower extremity chronic venous disease, peripheral vascular disease, and vasculitis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic venous disease</strong> – Venous insufficiency involving the lower extremities often presents with cutaneous hyperpigmentation, edema, and varicosities on the lower extremities. Ulceration can occur and is most often found near the medial malleolus. Ulcers are typically shallow with irregular borders and yellow, fibrinous exudate  (<a class="graphic graphic_picture graphicRef104173" href="/z/d/graphic/104173.html" rel="external">picture 5</a>). Atrophie blanche may also occur. The diagnosis often can be made clinically; venous ultrasonography can be helpful when the diagnosis is uncertain. (See  <a class="medical medical_review" href="/z/d/html/8198.html" rel="external">"Clinical manifestations of lower extremity chronic venous disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral vascular disease</strong> – Peripheral vascular disease of the lower extremities can result in ischemic ulcers, which are often located on the toes, heel, malleoli, or shin. The painful ulcers are well demarcated, with a "punched-out" appearance  (<a class="graphic graphic_picture graphicRef104174" href="/z/d/graphic/104174.html" rel="external">picture 6</a>). Peripheral pulses are diminished. The diagnosis can be substantiated through ankle-brachial index testing. (See  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasculitis</strong> – Vasculitis involving medium-sized cutaneous blood vessels (eg, cutaneous polyarteritis nodosa, antineutrophil cytoplasmic antibody [ANCA]-associated vasculitis, mixed cryoglobulinemia, thromboangiitis obliterans, lymphocytic thrombophilic arteritis) may present with subcutaneous nodules, ulcers, livedo reticularis, or livedo racemosa. A skin biopsy can differentiate livedoid vasculopathy from vasculitis. (See  <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis"</a>.)</p><p></p><p>Examples of other disorders in the differential diagnosis include pyoderma gangrenosum, factitial or traumatic skin injury, and the various additional causes of leg ulcers. An overview of the differential diagnosis of leg ulcers is provided separately. (See  <a class="medical medical_review" href="/z/d/html/13782.html" rel="external">"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/13680.html" rel="external">"Approach to the differential diagnosis of leg ulcers"</a>.)</p><p class="headingAnchor" id="H4243190975"><span class="h1">ADDITIONAL EVALUATION</span><span class="headingEndMark"> — </span>After the diagnosis of livedoid vasculopathy has been confirmed histologically, patients should be evaluated for underlying disorders. The evaluation should begin with a complete history, review of systems, and physical examination to assess for findings suggestive of thrombophilia or a systemic rheumatic disease. Although we typically perform laboratory testing for thrombophilia in all patients, we limit laboratory investigation for systemic rheumatic diseases to patients who exhibit other findings suggestive of such diseases. </p><p>Examples of studies often included in our laboratory assessment include:</p><p class="bulletIndent1"><span class="glyph">●</span>Tests for acquired and inherited thrombophilia (see  <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors", section on 'Hypercoagulable tests'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive metabolic panel</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte sedimentation rate and C-reactive protein</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid factor and antibodies to cyclic citrullinated peptides</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum complement levels (eg, CH50, C3, and C4)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antinuclear antibody titer</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antineutrophil cytoplasmic antibodies (ANCA)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum cryoglobulins </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum protein electrophoresis and immunofixation</p><p></p><p>The primary value in evaluating patients for a systemic rheumatic disease is the identification of patients at risk for other complications of the identified condition. Treatment of the underlying systemic rheumatic disease does not seem to have a consistent effect on livedoid vasculopathy, and the presence of a systemic rheumatic disease does not usually alter the approach to treatment. In contrast, the presence of thrombophilia influences our approach to treatment. (See <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of livedoid vasculopathy usually involves a combination of interventions. No single therapeutic approach is effective for all patients [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H3198028558"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Pain management and wound care are important components of management. Smoking cessation and compression also may be beneficial:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain management </strong>– Pain secondary to livedoid vasculopathy can be severe. Our first-line approach to pain management usually consists of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> or nonsteroidal anti-inflammatory drugs, such as <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a>. Treatments typically used for neuropathic pain, such as tricyclic drugs, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, may be useful for patients with recalcitrant ulcerations [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wound care </strong>– Wound care should involve maintenance of a moist wound environment and control of superinfection. General principles of wound management are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15912.html" rel="external">"Basic principles of wound management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking cessation </strong>– Although the effects of smoking cessation on livedoid vasculopathy have not been studied, we encourage patients to stop smoking because of the negative effects of smoking on wound healing. In addition, there is a proposed relationship between livedoid vasculopathy and smoking. In a series of 45 patients with livedoid vasculopathy evaluated at a tertiary care center in the United States, 47 percent reported a history of smoking [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/112216.html" rel="external">"Risk factors for impaired wound healing and wound complications", section on 'Smoking and nicotine replacement therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compression </strong>– Clinical experience suggests that compression therapy is beneficial in patients with associated venous insufficiency provided ankle-brachial index results do not suggest concomitant arterial insufficiency [<a href="#rid2">2</a>]. Improvement may be related to a stimulatory effect of compression on fibrinolytic activity [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency"</a>.)</p><p></p><p class="headingAnchor" id="H4262310548"><span class="h2">Pharmacologic therapy</span><span class="headingEndMark"> — </span>Limited data suggest that therapies that minimize risk for thrombosis, including antiplatelet, anticoagulant, and fibrinolytic agents, can improve livedoid vasculopathy [<a href="#rid2">2,12</a>]. Benefit from immunomodulatory, vasodilatory, and other interventions has also been reported. Combination therapy is often necessary.</p><p class="headingAnchor" id="H3476005225"><span class="h3">Our approach</span><span class="headingEndMark"> — </span>No randomized trials have evaluated therapies for livedoid vasculopathy, and the best approach to treatment is unclear. Our approach is reviewed here. Other approaches may be reasonable.</p><p>The antiplatelet agent <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, a generally well-tolerated and widely available oral agent, is our preferred first-line therapy for patients without an identified thrombophilia. We typically prescribe aspirin alone for initial therapy, though combination therapy with <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> is used by some clinicians. <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> is our favored initial treatment for patients who cannot tolerate aspirin. For patients who can tolerate aspirin but fail to improve on aspirin alone, we typically add pentoxifylline. </p><p>When patients have insufficient responses to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, we often proceed to anticoagulation. We typically use <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, low molecular weight (LMW) heparin, or a direct oral anticoagulant, such as <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>. Most patients respond to one of these agents. For our rare patients with refractory disease, we have had some success with tissue thrombolytic therapy (tissue plasminogen activator).</p><p>Our approach to patients with identified thrombophilia differs. Anticoagulants are often used as first-line therapy; however, selection of an initial agent should be based upon knowledge of the therapies known to reduce thrombosis in the specific thrombophilia.</p><p>There is no fixed endpoint for therapy in patients who respond to treatment. Discontinuation of treatment may be attempted after ulcer healing; however, continuous treatment may be necessary to maintain improvement.</p><p class="headingAnchor" id="H863641819"><span class="h3">Antiplatelet agents</span><span class="headingEndMark"> — </span>Improvement from treatment with antiplatelet agents, such as <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a>, and <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, has been reported.</p><p class="headingAnchor" id="H1554884976"><span class="h4">Aspirin with or without dipyridamole</span><span class="headingEndMark"> — </span>Case reports and case series document benefit from <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone or in combination with the antiplatelet agent <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> [<a href="#rid13">13-16</a>]. Aspirin is typically given to adult patients at a dose of 325 to 365 mg per day; the typical dose for dipyridamole is 75 mg four times per day. Improvement in signs and symptoms of livedoid vasculopathy are expected within the first few months of treatment. Adverse effects of aspirin are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p class="headingAnchor" id="H477966894"><span class="h4">Pentoxifylline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> can be given alone or in combination with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. In particular, pentoxifylline is a favorable initial treatment for patients who cannot tolerate aspirin. Pentoxifylline improves hyperviscosity of the blood and has inhibitory effects on platelet and erythrocyte aggregation. The drug has appeared helpful for livedoid vasculopathy in case series [<a href="#rid17">17,18</a>]. </p><p>Adults can be treated with 400 mg of <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> one to three times per day. Clinical improvement is expected within the first few months of treatment. Gastrointestinal distress is a potential side effect.</p><p class="headingAnchor" id="H1295876822"><span class="h3">Anticoagulants</span><span class="headingEndMark"> — </span>Improvement from treatment with anticoagulants, such as <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, heparin, and direct oral anticoagulants, has been reported.</p><p class="headingAnchor" id="H2816202134"><span class="h4">Warfarin or heparin</span><span class="headingEndMark"> — </span>Rapid clinical improvement during treatment with oral <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or subcutaneous LMW heparin is documented in case reports and case series [<a href="#rid12">12,19,20</a>]. Warfarin is dosed to achieve an international normalized ratio (INR) between 2 and 3 and may lead to marked improvement within the first two months of therapy [<a href="#rid21">21-23</a>]. The LMW <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> can be given subcutaneously as 1 mg/kg every 12 hours for six months followed by once daily treatment. Marked clinical improvement has occurred within the first few months of LMW heparin treatment [<a href="#rid24">24,25</a>]. Monitoring requirements and adverse effects of warfarin and LMW heparin are reviewed in detail separately. Warfarin is contraindicated in pregnancy. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H1464159552"><span class="h4">Direct oral anticoagulants</span><span class="headingEndMark"> — </span>Direct oral anticoagulants are newer options for anticoagulation that do not require the frequent monitoring necessary for <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> therapy and can be given orally, unlike LMW heparin therapy. In a 12-week uncontrolled study, treatment of 25 patients with painful livedoid vasculopathy with oral <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (10 mg twice daily with the option to reduce to once-daily dosing upon improvement) was associated with reduced pain, erythema, and ulceration [<a href="#rid26">26</a>]. Benefit of rivaroxaban and other direct oral anticoagulants, including <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>, and <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, is documented in case reports or case series [<a href="#rid12">12,27-31</a>]. Risks of direct oral anticoagulants are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H3267481990"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span>Other therapies that may be useful based upon case reports or small case series include tissue plasminogen activator (10 mg intravenously given for 14 days) [<a href="#rid32">32-34</a>], <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily), <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> (200 mg per day) [<a href="#rid26">26,35</a>], hyperbaric oxygen (1.5 to 2 hours for up to 15 treatment sessions) [<a href="#rid36">36</a>], intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (monthly infusions of 0.5 g/kg given over two or three consecutive days) [<a href="#rid37">37,38</a>], <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> (10 to 20 mg three times per day) [<a href="#rid39">39</a>], topical <a class="drug drug_general" data-topicid="8596" href="/z/d/drug information/8596.html" rel="external">becaplermin</a> [<a href="#rid40">40</a>], psoralen plus ultraviolet A (PUVA; 0.5 to 1 mJ/cm<sup>2</sup> per treatment session) [<a href="#rid41">41,42</a>], <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> (1 g three times per day) [<a href="#rid43">43,44</a>], endovenous ablation for associated venous insufficiency [<a href="#rid45">45</a>], <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid46">46,47</a>], <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid46">46,48,49</a>], <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid50">50,51</a>], and <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> [<a href="#rid46">46,52</a>].</p><p class="headingAnchor" id="H221185924"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Livedoid vasculopathy often recurs upon discontinuation of treatment. Long-term treatment with an effective regimen is usually necessary. </p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Livedoid vasculopathy is a chronic, recurrent, thrombo-occlusive vasculopathy of the distal lower extremities and feet that can lead to ulcer formation. Livedoid vasculopathy can occur independently or in the setting of a variety of thrombophilic states and underlying systemic disorders. (See <a class="local">'Associated disorders'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Characteristic clinical features of livedoid vasculopathy include livedoid changes, atrophie blanche (ivory-white plaques with peripheral hyperpigmentation and telangiectasias), painful ulcers, and edema. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– A skin biopsy is necessary to confirm the diagnosis. The biopsy should include the full thickness of the dermis as well as subcutaneous fat. The optimal sites for biopsy are at the edge of a new ulceration or over a new purpuric papule. The histologic findings that strongly support a diagnosis of livedoid vasculopathy include intraluminal thrombosis, endothelial proliferation, and subintimal hyaline degeneration in dermal blood vessels. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation </strong>– Livedoid vasculopathy may occur in association with thrombophilia and systemic rheumatic diseases. Patients diagnosed with livedoid vasculopathy should be assessed for these conditions. (See <a class="local">'Additional evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Data on treatment options for livedoid vasculopathy are limited, and the best approach to treatment is unclear:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General measures </strong>– Pain control and wound care are important components of management. Smoking cessation and compression may also be beneficial. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacologic therapy </strong>– Therapies reported as beneficial for livedoid vasculopathy have included antiplatelet, anticoagulant, fibrinolytic, immunomodulatory, and vasodilatory agents. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients without thrombophilia </strong>– For patients without an identified thrombophilia, we suggest <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> as initial treatment based upon case reports and case series that suggest benefit as well as the tolerability, wide availability, and low cost of this therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> is an alternative first-line treatment option that may be particularly useful for patients who cannot tolerate aspirin. Patients who do not respond to first-line treatments may benefit from other anticoagulants or other interventions. (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients with thrombophilia </strong>– Selection of treatment for patients diagnosed with thrombophilia is based upon knowledge of the therapies known to reduce thrombosis in the specific thrombophilia. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="headingAnchor" id="H2348512549"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John Stone, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jorizzo JL. Livedoid vasculopathy: what is it? Arch Dermatol 1998; 134:491.</a></li><li><a class="nounderline abstract_t">Alavi A, Hafner J, Dutz JP, et al. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. J Am Acad Dermatol 2013; 69:1033.</a></li><li><a class="nounderline abstract_t">Soulages A, Maisonobe T, Auzou P, et al. Peripheral neuropathy and livedoid vasculopathy. J Neurol 2022; 269:3779.</a></li><li><a class="nounderline abstract_t">Hairston BR, Davis MD, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol 2006; 142:1413.</a></li><li><a class="nounderline abstract_t">Bard JW, Winkelmann RK. Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967; 96:489.</a></li><li><a class="nounderline abstract_t">Alegre VA, Gastineau DA, Winkelmann RK. Skin lesions associated with circulating lupus anticoagulant. Br J Dermatol 1989; 120:419.</a></li><li><a class="nounderline abstract_t">Grob JJ, Bonerandi JJ. Thrombotic skin disease as a marker of the anticardiolipin syndrome. Livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity. J Am Acad Dermatol 1989; 20:1063.</a></li><li><a class="nounderline abstract_t">Valentim FO, Tsutsui GM, Miot HA. Recrudescence of livedoid vasculopathy induced by COVID-19. Int J Dermatol 2021; 60:e185.</a></li><li><a class="nounderline abstract_t">Nuttawong S, Chularojanamontri L, Trakanwittayarak S, et al. Direct immunofluorescence findings in livedoid vasculopathy: a 10-year study and literature review. Clin Exp Dermatol 2021; 46:525.</a></li><li><a class="nounderline abstract_t">Vasudevan B, Neema S, Verma R. Livedoid vasculopathy: A review of pathogenesis and principles of management. Indian J Dermatol Venereol Leprol 2016; 82:478.</a></li><li><a class="nounderline abstract_t">Allenby F, Boardman L, Pflug JJ, Calnan JS. Effects of external pneumatic intermittent compression on fibrinolysis in man. Lancet 1973; 2:1412.</a></li><li><a class="nounderline abstract_t">Micieli R, Alavi A. Treatment for Livedoid Vasculopathy: A Systematic Review. JAMA Dermatol 2018; 154:193.</a></li><li><a class="nounderline abstract_t">Yang LJ, Chan HL, Chen SY, et al. Atrophie blanche. A clinicopathological study of 27 patients. Changgeng Yi Xue Za Zhi 1991; 14:237.</a></li><li><a class="nounderline abstract_t">El Khoury J, Taher A, Kurban M, et al. Livedoid vasculopathy associated with sickle cell trait: significant improvement on aspirin treatment. Int Wound J 2012; 9:344.</a></li><li><a class="nounderline abstract_t">Maessen-Visch MB, Koedam MI, Hamulyák K, Neumann HA. Atrophie blanche. Int J Dermatol 1999; 38:161.</a></li><li><a class="nounderline abstract_t">Drucker CR, Duncan WC. Antiplatelet therapy in atrophie blanche and livedo vasculitis. J Am Acad Dermatol 1982; 7:359.</a></li><li><a class="nounderline abstract_t">Sauer GC. Pentoxifylline (Trental) therapy for the vasculitis of atrophie blanche. Arch Dermatol 1986; 122:380.</a></li><li><a class="nounderline abstract_t">Sams WM Jr. Livedo vasculitis. Therapy with pentoxifylline. Arch Dermatol 1988; 124:684.</a></li><li><a class="nounderline abstract_t">Gardette E, Moguelet P, Bouaziz JD, et al. Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options. Acta Derm Venereol 2018; 98:842.</a></li><li><a class="nounderline abstract_t">Weishaupt C, Strölin A, Kahle B, et al. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis. J Eur Acad Dermatol Venereol 2019; 33:1784.</a></li><li><a class="nounderline abstract_t">Davis MD, Wysokinski WE. Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin. J Am Acad Dermatol 2008; 58:512.</a></li><li><a class="nounderline abstract_t">Kavala M, Kocaturk E, Zindanci I, et al. A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin. J Dermatolog Treat 2008; 19:121.</a></li><li><a class="nounderline abstract_t">Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006; 142:75.</a></li><li><a class="nounderline abstract_t">Hairston BR, Davis MD, Gibson LE, Drage LA. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol 2003; 139:987.</a></li><li><a class="nounderline abstract_t">Abou Rahal J, Ishak RS, Otrock ZK, et al. Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin. J Thromb Thrombolysis 2012; 34:541.</a></li><li><a class="nounderline abstract_t">Weishaupt C, Strölin A, Kahle B, et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 2016; 3:e72.</a></li><li><a class="nounderline abstract_t">Lee JS, Cho S. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment. J Eur Acad Dermatol Venereol 2020; 34:e176.</a></li><li><a class="nounderline abstract_t">Evans JM, Jensen JD, Sami N. Successful treatment of livedoid vasculopathy with rivaroxaban. JAAD Case Rep 2015; 1:340.</a></li><li><a class="nounderline abstract_t">Yamaguchi Y, Nakazato S, Izumi K, et al. Rapid remission of severe pain from livedoid vasculopathy by apixaban. J Eur Acad Dermatol Venereol 2017; 31:e45.</a></li><li><a class="nounderline abstract_t">Furukawa F, Mizawa M, Makino T, Shimizu T. Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Sawada T, Suehiro M. Dabigatran in the management of livedoid vasculopathy. Clin Exp Dermatol 2017; 42:237.</a></li><li><a class="nounderline abstract_t">Antunes J, Filipe P, André M, et al. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy. Acta Derm Venereol 2010; 90:91.</a></li><li><a class="nounderline abstract_t">Klein KL, Pittelkow MR. Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc 1992; 67:923.</a></li><li><a class="nounderline abstract_t">Johnson DW, Hawley CM, Strutton G, Gibbs HH. Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA). Aust N Z J Med 1995; 25:370.</a></li><li><a class="nounderline abstract_t">Kerk N, Drabik A, Luger TA, et al. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy. Br J Dermatol 2013; 168:898.</a></li><li><a class="nounderline abstract_t">Juan WH, Chan YS, Lee JC, et al. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy. Br J Dermatol 2006; 154:251.</a></li><li><a class="nounderline abstract_t">Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 2004; 51:574.</a></li><li><a class="nounderline abstract_t">Kofler K, Strölin A, Geiger V, Kofler L. Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level. J Cutan Med Surg 2021; 25:504.</a></li><li><a class="nounderline abstract_t">Purcell SM, Hayes TJ. Nifedipine treatment of idiopathic atrophie blanche. J Am Acad Dermatol 1986; 14:851.</a></li><li><a class="nounderline abstract_t">Mushtaq S, Singh S, Mudugal R. Topical becaplermin gel is an effective adjuvant for long-standing ulcers of livedoid vasculopathy recalcitrant to anticoagulant therapy. Clin Exp Dermatol 2019; 44:681.</a></li><li><a class="nounderline abstract_t">Lee JH, Choi HJ, Kim SM, et al. Livedoid vasculitis responding to PUVA therapy. Int J Dermatol 2001; 40:153.</a></li><li><a class="nounderline abstract_t">Tuchinda C, Leenutaphong V, Sudtim S, Lim HW. Refractory livedoid vasculitis responding to PUVA: a report of four cases. Photodermatol Photoimmunol Photomed 2005; 21:154.</a></li><li><a class="nounderline abstract_t">Bisalbutra P, Kullavanijaya P. Sulfasalazine in atrophie blanche. J Am Acad Dermatol 1993; 28:275.</a></li><li><a class="nounderline abstract_t">Gupta AK, Goldfarb MT, Voorhees JJ. The use of sulfasalazine in atrophie blanche. Int J Dermatol 1990; 29:663.</a></li><li><a class="nounderline abstract_t">Chow M, Swift R, Sutton A, Wysong A. Endovenous Laser Ablation Treatment for Lower Extremity Ulcers Associated With Livedoid Vasculopathy. Dermatol Surg 2020; 46:853.</a></li><li><a class="nounderline abstract_t">Gao Y, Jin H. Real-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy. J Eur Acad Dermatol Venereol 2022; 36:e46.</a></li><li><a class="nounderline abstract_t">Gao Y, Jin H. Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis. J Dermatolog Treat 2022; 33:178.</a></li><li><a class="nounderline abstract_t">Huang XW, Zheng HX, Wang ML, et al. Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines (Basel) 2022; 10.</a></li><li><a class="nounderline abstract_t">Dong L, Li Q, Yu Y, et al. Efficacy of adalimumab in the treatment of refractory livedoid vasculopathy: Case report and literature review. Dermatol Ther 2022; 35:e15666.</a></li><li><a class="nounderline abstract_t">Alix JJ, Hadjivassiliou M, Ali R, et al. Sensory ganglionopathy with livedoid vasculopathy controlled by immunotherapy. Muscle Nerve 2015; 51:296.</a></li><li><a class="nounderline abstract_t">Zeni P, Finger E, Scheinberg MA. Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy. Ann Rheum Dis 2008; 67:1055.</a></li><li><a class="nounderline abstract_t">Jia E, Yan G, Xiao M, et al. Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib. Dermatol Ther 2020; 33:e14470.</a></li></ol></div><div id="topicVersionRevision">Topic 4684 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554303" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Livedoid vasculopathy: what is it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24028907" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35166926" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Peripheral neuropathy and livedoid vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116831" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Livedoid vasculopathy: further evidence for procoagulant pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6054223" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2496741" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Skin lesions associated with circulating lupus anticoagulant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2502566" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thrombotic skin disease as a marker of the anticardiolipin syndrome. Livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33527356" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recrudescence of livedoid vasculopathy induced by COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32986882" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Direct immunofluorescence findings in livedoid vasculopathy: a 10-year study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27297279" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Livedoid vasculopathy: A review of pathogenesis and principles of management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4128724" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effects of external pneumatic intermittent compression on fibrinolysis in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141075" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment for Livedoid Vasculopathy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1797367" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Atrophie blanche. A clinicopathological study of 27 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22044499" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Livedoid vasculopathy associated with sickle cell trait: significant improvement on aspirin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10208608" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Atrophie blanche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7130497" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antiplatelet therapy in atrophie blanche and livedo vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954406" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pentoxifylline (Trental) therapy for the vasculitis of atrophie blanche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3364993" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Livedo vasculitis. Therapy with pentoxifylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29738044" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31009111" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280355" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18484430" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415390" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925383" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592843" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26853646" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31793049" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27051773" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Successful treatment of livedoid vasculopathy with rivaroxaban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27166520" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Rapid remission of severe pain from livedoid vasculopathy by apixaban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28739563" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052437" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dabigatran in the management of livedoid vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20107738" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1434852" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tissue plasminogen activator for treatment of livedoid vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8540885" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23106384" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433793" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389193" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33779349" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3711393" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nifedipine treatment of idiopathic atrophie blanche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30706539" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Topical becaplermin gel is an effective adjuvant for long-standing ulcers of livedoid vasculopathy recalcitrant to anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328402" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Livedoid vasculitis responding to PUVA therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888134" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Refractory livedoid vasculitis responding to PUVA: a report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8094403" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sulfasalazine in atrophie blanche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1980268" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The use of sulfasalazine in atrophie blanche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882502" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Endovenous Laser Ablation Treatment for Lower Extremity Ulcers Associated With Livedoid Vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34416092" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Real-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32116074" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35455298" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Adalimumab in Treating Refractory Livedoid Vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35760761" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of adalimumab in the treatment of refractory livedoid vasculopathy: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25196820" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sensory ganglionopathy with livedoid vasculopathy controlled by immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18556452" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33112475" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
